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Abstract
Protein kinase CK2 is a highly conserved and constitutively active Ser/Thr-kinase that phosphorylates a large number of
substrates, resulting in increased cell proliferation and survival. A known target of CK2 is Akt, a player in the PI3K/Akt/
mTORC1 signaling pathway, which is aberrantly activated in 32% of colorectal cancer (CRC) patients. On the other
hand, mTORC1 plays an important role in the regulation of protein synthesis, cell growth, and autophagy. Some
studies suggest that CK2 regulates mTORC1 in several cancers. The most recently developed CK2 inhibitor, silmitasertib
(formerly CX-4945), has been tested in phase I/II trials for cholangiocarcinoma and multiple myeloma. This drug has
been shown to induce autophagy and enhance apoptosis in pancreatic cancer cells and to promote apoptosis in non-
small cell lung cancer cells. Nevertheless, it has not been tested in studies for CRC patients. We show in this work that
inhibition of CK2 with silmitasertib decreases in vitro tumorigenesis of CRC cells in response to G2/M arrest, which
correlates with mTORC1 inhibition and formation of large cytoplasmic vacuoles. Notably, molecular markers indicate
that these vacuoles derive from massive macropinocytosis. Altogether, these findings suggest that an aberrantly
elevated expression/activity of CK2 may play a key role in CRC, promoting cell viability and proliferation in untreated
cells, however, its inhibition with silmitasertib promotes methuosis-like cell death associated to massive catastrophic
vacuolization, accounting for decreased tumorigenicity at later times. These characteristics of silmitasertib support a
potential therapeutic use in CRC patients and probably other CK2-dependent cancers.
Introduction
Colorectal cancer (CRC) is a multifactorial disease
affecting millions of people worldwide and has been
linked to deregulation of several signaling pathways. The
PI3K/Akt signaling pathway plays an important role in a
variety of cancers due to its association with processes
that promote proliferation, resistance to apoptosis,
invasion, and metastasis1. In CRC, a number of genetic
and epigenetic alterations have been described, for
example, activating mutations in the PI3K kinase gene
have been identified in 32% of tumors2, as well as loss of
function mutations of the tumor suppressor PTEN3. All
these alterations contribute to the aberrant activation of
the PI3K/Akt signaling pathway and, in consequence,
acquisition of a metastatic phenotype4.
A key downstream component of the PI3K/Akt signal-
ing pathway is the mammalian target of rapamycin
complex 1 (mTORC1), which plays an important role in
different types of cancer, including CRC4,5. The core
component of this complex, the mammalian target of
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rapamycin (mTOR), is a highly conserved Ser/Thr-kinase
that integrates growth factor and nutritional signals to
promote growth and survival of normal cells. Activation
of mTORC1 leads to phosphorylation of mediators of
protein translation and cell growth, including the ribo-
somal S6 kinase 1 (S6K1) and 4EBP16,7. MTORC1 plays
an important role in the regulation of protein synthesis,
cell growth and autophagy in response to nutrients and
growth factors8. Inactivation of TSC2 by Akt favors the
activation of Rheb, which interacts and activates
mTORC1 at the lysosomal membrane8,9. Inhibition
mTORC1 was shown to decrease formation of polyps,
oncogenesis, and mortality of ApcΔ716 mice10. Also,
treatment with rapamycin leads to a reduction of tumors
in an in vivo model of PI3K-dependent CRC11.
Autophagy is initiated by ULK-1, which is activated
under nutrient deprivation or mTORC1 inhibition by
rapamycin12–14. Autophagy is associated to a number of
diseases, although its role in tumorigenesis and progres-
sion is controversial12,15. Some studies show that autop-
hagy suppresses tumorigenesis15,16, while in others
autophagy inhibition by silencing Rheb decreases survival
of Colo320HSR colon cancer cells17. Likewise, autophagy
inhibition exerts an anticancer effect in HCT-116 colon
cancer cells by triggering apoptosis18. Conversely, a dual
inhibitor of mTORC1/2, WYE354, induces autophagy and
activates apoptosis in HCT-116 and HT-29 colon cancer
cells19. Finally, Beclin-1 overexpression correlates with a
positive prognosis and survival of CRC patients20.
Protein kinase CK2 has been proposed as a therapeutic
target in various cancers. CK2 is a highly conserved
constitutively active Ser/Thr-kinase capable of phos-
phorylating a large number of substrates, increasing
proliferation, and survival21–23. CK2 is able to control
mTORC1 in several cancers. In fact, CK2 regulates the
PI3K/Akt pathway through phosphorylation of Akt at Ser-
129, causing its hyperactivation24,25. Thus, CK2 silencing
has been tested and greater effort dedicated to study
specific inhibitors for therapy. The latest developed CK2
inhibitor, silmitasertib (formerly CX-4945), displays
excellent pharmacological properties, which rendered it
suitable for evaluation in phase I/II trials for cholangio-
carcinoma and multiple myeloma (clinicaltrials.gov).
Despite it has not yet been included in studies for CRC
patients, it induces in vitro autophagy and enhances
apoptosis in pancreatic cancer cells26, as well as promotes
apoptosis in non-small cell lung cancer cells by inhibiting
the PI3K/Akt/mTOR pathway27. In addition, silmitasertib
induces apoptosis in epidermoid carcinoma and
squamous carcinoma cells by a complete inhibition of
the PI3K/Akt/mTOR pathway in combination with
erlotinib28.
Here, we show that an aberrantly elevated expression/
activity of CK2 may play an undescribed role in viability of
CRC cells. Thus, CK2 inhibition with silmitasertib pro-
motes an early methuosis-like cell death, which is asso-
ciated to massive catastrophic macropinocytosis,
accounting for abolition of tumorigenicity at later stages.
These results support the use of silmitasertib as a pro-
missory therapeutic alternative in the treatment of CRC
patients.
Results
CK2 inhibition decreases tumorigenesis of CRC cells
through a G2/M arrest
Tumorigenic cells have the in vitro capacity of
anchorage-independent growth and forming colonies in
soft-agar. Thus, we studied whether CK2 inhibition could
decrease clonogenesis of DLD-1 cells after 21 days of
treatment with increasing concentrations of silmitasertib.
A significant dose-dependent decrease in both number
and size of the colonies was observed (Fig. 1), suggesting a
potent effect of silmitasertib in decreasing CRC tumor-
igenesis. To elucidate the underlying mechanism, a ten-
fold shorter time was used to evaluate whether
silmitasertib affects the viability of DLD-1 and other CRC
cells of different malignancy29. SW-480 (Dukes B state),
DLD-1 (Dukes C state), HT-29 (Dukes C/D state), and
HCT-116 (Dukes D state) cells were grown with or
without 25 μM silmitasertib for 48 h. Viability of all CRC
cells decreased 60–70%, while normal colon epithelial
CoN cells only decreased just over 30% (Fig. 2a).
Decreased viability of CRC cells correlated with dimin-
ished proliferation (Fig. 2b) and late apoptosis, as
observed by PARP-1 cleavage and annexin-V+/PI+
staining after 48 h (Fig. 2c, d), however, the pan-caspase
inhibitor Z-VAD-FMK was unable to revert the decreased
viability both at 24 h and 48 h (Supp Fig. 1A). Since
double annexin-V+/PI+ staining is also related to early
necrosis/necroptosis, we assessed whether the decreased
viability may probably derive from this at 48 h. The
necroptosis inhibitor, necrostatin-1s (Nec1s), did not
revert the viability neither at 24 h nor at 48 h (Supp
Fig. 1B). Additionally, localization of High Mobility Group
Box 1 (HMGB1) transcription factor, which is exported to
the cytoplasm during early necrosis30, showed only a
minimal cytoplasmic localization at 12 h of treatment
(Supp Fig. 1C).
A more specific analysis of silmitasertib treatment on
cell cycle was performed. This analysis showed a basal
sub-G0 fraction at 16 h (Fig. 3a) that was maintained at 24
h (Fig. 3b) but, as expected, significantly progressed at 48
h (Fig. 3c). In parallel, a reduction in the G0/G1 fraction
was already observed at 16 h, which progressed through
24 h and further at 48 h. Notably, an increase in G2/M
arrest was observed at 24 h, which was much more ele-
vated at 48 h of treatment. Activating mutation of the
PIK3CA gene is a common trait in CRC tumors, leading
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to aberrant activation of the PI3K/Akt pathway2, however,
silmitasertib triggered the same G2/M arrest in SW-480
cells (Supp Fig. 2) which, unlike DLD-1, does not contain
activating mutations in PIK3CA. These results suggest an
effect of the CK2 inhibitor silmitasertib on decreasing
tumorigenicity of CRC cells through a G2/M arrest.
CK2 regulates mTORC1 activity in CRC cells
Since mTORC1 is activated during mitosis and is
therefore important in G2/M cell cycle progression, as
well as in maintaining genomic integrity during this per-
iod27,31–34, we assessed whether the G2/M arrest could be
a consequence of reduced mTOR activity. Thus, phos-
phorylations on S6K1 at Thr389 and S6 at Ser235/Ser236
were used as activity markers of kinases mTORC1 and
S6K1, respectively. As observed in Fig. 4a, treatment with
silmitasertib for 16 h led to reduced activity of both
kinases. To confirm that the effect on mTORC1 is specific
of CK2, expression of CK2α was decreased with a specific
siRNA35 and levels of pT389-S6K1 were analyzed. Con-
cordantly, a similar decrease in pT389-S6K1 levels was
observed as early as 16 h upon silencing of CK2α (Fig. 4b).
Given that mTORC1 is activated by Akt, we evaluated
whether Akt overexpression reversed the negative effect
of silmitasertib on mTORC1-dependent phosphorylation
of S6K1. Overexpression of full-length wild-type Akt
(Akt-WT) did not reverse the decrease in mTORC1
activity after inhibition of CK2 (Fig. 4c). CK2 is also
described to phosphorylate Akt at Ser-129, which is
important for the Wnt/β-catenin pathway in HEK-293
cells36,37. We analyzed whether overexpression of a
mutant Akt unable to be phosphorylated by CK2 (Akt-
S129A) had an effect on mTORC1 activity. The inability
of being phosphorylated by CK2 slightly precluded Akt-
S129A of activating mTORC1 (Fig. 4d and Supp Fig. 3A),
which probably affected its capability to increase viability
(Fig. 4e), however, it did not affect the augmented
migration of Akt-S129A-expressing cells as compared to
Akt-WT cells (Fig. 4f). This suggests that Ser-129 is
somehow important for promoting viability of DLD-1
cells by probably promoting a full activation of mTORC1,
which is evidenced for a slight decrease of pT389-S6K1.
However, this residue would be expendable for the PI3K/
Akt-promoted migration.
Nutrients and growth factors, as well as altered PI3K/
Akt signaling, have been shown to promote subcellular
Fig. 1 CK2 inhibition with silmitasertib decreases in vitro tumorigenesis of CRC cells. Anchorage-independent colony growth in soft-agar was
determined in DLD-1 cells treated with increasing concentrations of silmitasertib for 21 days. a Representative images of colonies in soft-agar of
control (white bars) and silmitasertib-treated (black bars) cells. The number of colonies per well (b) and area of colonies (c) was plotted. Data
represents the average ± SEM (n= 3); ****p < 0.0001; ns, not significant. Bar: 20 μm
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localization of mTORC1 to the outer layer of lysosomal
membranes, where it is activated by Rheb6,8,9. We eval-
uated whether silmitasertib affected the localization of
mTORC1 at lysosomes of DLD-1 cells. As early as 6 h,
untreated cells showed perinuclear localization of lyso-
somes with the expected colocalization of mTORC1,
while in treated cells lysosomes were more disperse and
apparently smaller, and their colocalization with
mTORC1 was reduced (Supp Fig. 3B), suggesting that
CK2 inhibition hindered localization of mTORC1 to
lysosomes and probably its activation by Rheb. MTORC1
is also known to be a key regulator of autophagy38. In fact,
mTORC1 inhibition has been linked to augmented
autophagy in different cancer cell lines8,19,39. Lysosomal
Rheb-activated mTORC1 inhibits ULK-1 by phosphor-
ylation at Ser757, which is key for early autophagy
induction13,14. Thus, augmented pSer757-ULK-1 levels
are a good marker of autophagy blockage. Therefore, to
assess whether CK2 inhibition could have an impact on
the activation of ULK-1, cells were treated with silmita-
sertib for 6 h, following analysis of mTORC1 and ULK-1
phosphorylation by western blot. As expected, silmita-
sertib led to decreased levels of mTORC1-dependent
phosphorylation in both targets, pT389-S6K1 and
pS757-ULK-1 (phospho-inhibitory site), thus meaning
that mTORC1 and ULK-1 were inhibited and more active
(i.e., less-inhibited), respectively, as compared with
untreated cells (Supp Fig. 3C). Altogether, these results
indicate that CK2 inhibition may lead to inactivation of
mTORC1 in CRC cells.
Silmitasertib-dependent mTORC1 inhibition leads to
formation of large vacuoles
The onset of autophagy by ULK-1 activation normally
leads to phagophore formation, which then fuses with
lysosomes to form an autophagolysosome13. Interestingly,
massive large cytosolic vacuoles formed only in CRC cell
lines treated for 6 h with silmitasertib and not in normal
CoN cells (Fig. 5a and Supp Fig. 4A). In DLD-1 cells, a
progressive dose-dependent increase of small (<3 μm)
vacuoles was observed with silmitasertib up to 12 h. At
higher times, the number of vacuoles decreased con-
comitant with the increase in silmitasertib concentration
while displaying an increase in their size, suggesting a
fusion of small vacuoles to form bigger structures of
almost 5–6 μm. At both higher silmitasertib concentra-
tions and treatment times, a cellular collapse was evi-
denced by large birefringent structures, indicative of
Fig. 2 Silmitasertib decreases viability and proliferation of CRC cells. a Cell viability was determined by MTS assay in normal (CoN) and CRC cells
(SW-480, DLD-1, HT-29, and HCT-116) after incubation with either vehicle (white bars) or 25 μM silmitasertib (black bars) for 48 h. b DLD-1 cells were
treated as in a and proliferation was determined by CFSE staining and cytometry. c Protein levels of caspase-cleaved PARP-1 were detected by
western blot in DLD-1 and HT-29 cells treated as in a. d DLD-1 cells treated with 25 μM silmitasertib for 24 and 48 h were analyzed through double
positive annexin-V-FITC/PI staining by cytometry. Data represents the average ± SEM (n= 3); *p < 0.05
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massive cell death (Fig. 5b–d). In addition, viability
decreased in a time-dependent manner, showing
significance after 12 h (Supp Fig. 4B). Interestingly, the
number of small (<2 μm) vacuoles progressively increased
up to 24 h, while significantly dropping at 48 h, which
correlated with a significant increase of large (>4.5 μm)
vacuoles. To confirm that the effect of silmitasertib on
vacuole formation is caused by specific inhibition of CK2,
expression of CK2α was silenced with the same siRNA as
above (see Fig. 4b). Thus, CK2 silencing was sufficient to
produce massive vacuole formation (≈4 μm), which pro-
gressed both in number and size in time, reaching larger
structures (>5 μm) after 24 h of cell growth, resembling
those triggered by silmitasertib at either 25 μM for 48 h or
50 μM for 24 h (Fig. 5e). As control, DLD-1 cells were
treated with 100 ng/ml nocodazole for 24 h, which was
unable to preclude the silmitasertib-dependent massive
vacuolization and thus discarding that this process is
product of a G2/M arrest (Supp Fig. 4C).
To investigate whether those vacuoles correspond to
autophagolysosomes, DLD-1 cells were loaded with
lysotracker, which fluoresces in acidic pH like in lyso-
somes. As observed in Fig. 6a, vacuoles formed by treat-
ment with silmitasertib were marked with lysotracker,
indicating an acidic inner environment and which, due to
their large size, could correspond to autophagolysosomes.
During autophagy, ULK-1 phosphorylates and activates a
class III PI3K, promoting the docking of the ubiquitin-like
factor LC3-II to autophagolysosome membranes, which
binds to its receptor p62 and together are ultimately
degraded at the expanding autophagolysosome13. Thus, to
assess whether silmitasertib-dependent ULK-1 activation
and vacuolization are related to induction of autophagy,
GFP-LC3 protein was expressed in DLD-1 cells and its
subcellular distribution was evaluated after treatment
with silmitasertib up to 12 h. Unexpectedly, untreated
control cells showed GFP-tagged structures suggesting
docking of LC3 at autophagolysosomes, which diminished
after treatment for 6 h and almost completely after 12 h.
Importantly, large vacuoles already present at 6 h did not
recruit GFP-LC3 to their membranes at 12 h (Fig. 6b and
Supp Fig. 5A). Indeed, similar results were obtained in
HeLa cervical cancer cells, where large vacuoles formed
under treatment with silmitasertib, which were also GFP-
LC3-negative (Supp Fig. 5B). Additionally, decreased
LC3-II and p62 levels were observed in DLD-1 cells
treated with silmitasertib and bafilomycin-A1, an inhi-
bitor of autophagic flow, for a period of up to 18 h (Fig. 6c,
d). Importantly, this phenomenon was not related to de
novo expression of representative autophagy genes, such
as Beclin-1 and LC3 (Supp Fig. 5C) and vacuole formation
was not blocked by inhibition of autophagy with 3-
methyladenine (Supp Fig. 5D), inhibition of apoptosis
with Z-VAD-FMK (Supp Fig. 5E), or inhibition of
necroptosis with Nec1s (Supp Fig. 5F). Thus, our results
suggest that silmitasertib-dependent mTORC1 inhibition,
Fig. 3 Silmitasertib induces G2/M arrest in CRC cells. Cell cycle
distribution was determined by flow cytometry of PI-stained DLD-
1 cells untreated (white bars) or treated (black bars) with 25 μM
silmitasertib for 16 h (a), 24 h (b), and 48 h (c). The percentage of cells
in the different cell cycle phases is plotted. Data represents the
average ± SEM (n= 3), *p < 0.05
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despite leading to the formation of acidic large LC3-
negative vacuoles, they do not derive from induction of
either autophagy, apoptosis or necroptosis.
Vacuoles derive from a massive silmitasertib-dependent
macropinocytosis
Since the large acidic vacuoles induced by silmitasertib
do not have LC3 on their membranes, they could corre-
spond to an endosomal compartment distinct from
autophagolysosomes. Interestingly, we observed that
silmitasertib-dependent vacuolization is precluded by
bafilomycin-A1 treatment (Supp Fig. 5A), which has been
shown to impair the macropinocytosis pathway else-
where40. Moreover, the late endosomal marker Rab7 has
been reported as an indicator of macropinosomes41,42.
Indeed, early large vacuoles formed after treatment with
silmitasertib were significantly Rab7 positive at 6 h
(Fig. 7a). Similarly, another late endosomal marker,
LAMP1, was also located at the membrane of such
vacuoles after treatment with silmitasertib (Supp Fig. 6).
Therefore, silmitasertib-promoted vacuoles in CRC cells
correspond to an endolysosomal compartment similar to
macropinosomes.
Because macropinocytosis is an endocytic pathway that
mediates non-selective uptake of solutes, we used dextran
to confirm the endocytic nature of the silmitasertib-
derived vacuoles. An internalization assay was performed
using 10 kDa FITC-conjugated dextran. Cells were treated
with silmitasertib during 6 h and then incubated with
dextran for 1 h. Consistently, control cells showed a
constitutive level of endocytosis, however, the green
fluorescence was concentrated at the large vacuoles
observed following treatment with silmitasertib (Fig. 7b).
Taken together, these results strongly suggest that inhi-
bition of CK2 with silmitasertib leads to massive macro-
pinocytosis in CRC cells.
Fig. 4 Decreased mTORC1 activity in CRC cells treated with silmitasertib. a DLD-1 cells were incubated with 25 μM silmitasertib for 16 h. The
levels of the indicated proteins were analyzed by western blot. b Cells were transfected with 100 nM of a specific siRNA for CK2α. The indicated
proteins were analyzed by western blot. c Cells were transfected with the plasmid pCMV6-myr-AKT-1-CA-HA and then treated with 25 μM
silmitasertib for 16 h. Protein levels were analyzed by western blot. d Levels of indicated proteins in cells transfected with the plasmids pCMV6-myr-
AKT-1-CA-HA or pCMV6-myr-AKT-1-S129A-HA were analyzed by western blot. e Cell viability determined by MTS assay of cells transfected as in
d. f Cell migration determined by transwell assay of cancer cells transfected as in d. Data represents the average ± SEM (n= 3); **p < 0.001; ****p <
0.0001; ns: not significant
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Fig. 5 MTORC1 inhibition correlates with ULK-1 activation and large acidic vacuoles. a Colon cancer (SW-480, DLD-1, HT-29, and HCT-116) and
non-tumor (CoN) cells were treated with 25 μM silmitasertib for 6 h and photographed under a phase-contrast microscope. b DLD-1 cells were treated
with silmitasertib at increasing concentrations (12.5, 25, and 50 μM) for different times (3, 6, 12, 24, and 48 h) and photographed under a phase-contrast
microscope. Images taken at 20x were processed for quantification of number (c) and size (d) of vacuoles per single cell as in Materials and methods.
e DLD-1 cells were transfected with either a specific siRNA for CK2α or a scrambled siRNA (control) by using Lipofectamine 2000 at a 1:3 ratio. Phase-
contrast images were obtained at 0, 6, and 24 h post-transfection and quantification of size (gray bars) and number of vacuoles per single cell (black
bars) were determined. Data represents the average ± SEM (n= 3); *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; ns: not significant. Bar: 20 μm
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Discussion
Protein kinase CK2 is elevated in different cancers
including CRC and its expression and activity are strongly
linked to hyperproliferation and resistance to apoptosis,
suggesting an important role in tumorigenesis21. In fact,
CK2 has been proposed as a putative prognostic marker in
cancer43–45. Consistently, an idea has emerged that some
tumor cells become “CK2-addicted” in order to create a
permissive microenvironment for tumor progression and
to eventually favor an aggressive phenotype23. Thus,
inhibition of CK2 should be extremely catastrophic in
those cancer cells. Therefore, CK2 has evolved as an
attractive therapeutic target in cancer, with two pharma-
cological inhibitors extensively used in in vitro and ex vivo
experiments, TBB (4,5,6,7-tetrabromobenzotriazole) and
silmitasertib (formerly CX-4945), the latter having been
tested in clinical trials. Both are CK2 competitive inhibi-
tors for the ATP binding site, normally used at the
micromolar scale by us and other groups46,47. However,
silmitasertib had a more potent effect than TBB in
decreasing viability of CRC cells, since a four-fold lower
concentration of the former was used in this work to
achieve the same effect (data not shown). Indeed, DLD-1
cells showed significant decrease in in vitro tumorigenesis
after 21 days, accounting for an extremely deleterious
effect of silmitasertib on cell viability. This correlated with
early cell cycle arrest at G2/M, previously seen in breast,
lung and glioblastoma cancer cells27,48,49. Of note, the
silmitasertib-dependent arrest in our DLD-1 cells was
distinct to what we observed in HT-29 cells treated with
TBB for 24 h35. Also relevant, the G2/M arrest was irre-
spective of activating mutations in the PIK3CA gene, a
common trait found in CRC tumors2, since the same was
observed in SW-480 cells, which are free of the genomic
alteration. This suggests a specific and broad effect of
silmitasertib on any CRC cell, endorsing its use in CRC
patient therapy in the future.
Our data show that CK2 may activate the PI3K/Akt/
mTORC1 signaling pathway in CRC. It has been described
that silmitasertib inhibits this pathway and hence decrea-
ses viability of lung cancer cells27. Additionally, silmita-
sertib in combination with erlotinib (an EGFR inhibitor)
produces a complete inhibition of this pathway, inducing
apoptosis in squamous lung cancer cells28. Moreover, two
pharmacological inhibitors of mTORC1, everolimus and
temsirolimus, exemplify the therapeutic importance of the
inhibition of this pathway in patients with advanced renal
carcinoma50. Thus, taking into consideration our pub-
lished findings on the functional relationship between CK2
and Akt36,37, an attractive possibility emerged where CK2
may eventually upregulate mTORC1 via phosphorylation/
activation of Akt in CRC cells. However, overexpression of
the CK2-phosphorylation resistant mutant, Akt-S129A,
behaved similarly to wild-type Akt on mTORC1 activity.
This could be a consequence of an mTORC1-independent
effect since activation of mTORC1 by Akt involves dif-
ferent proteins. For example, CK2 may alter the activity of
the Rags proteins, which are responsible for mTORC1
anchorage at the lysosome membrane51.
Silmitasertib-dependent inhibition of mTORC1 has
been seen to promote autophagy in lung, pancreas and
glioblastoma cancer cells, where inhibition of CK2 led to
inhibition of mTORC1 and displayed features of autop-
hagy26,27,52. Interestingly, it has also been described that a
decrease in the expression and activity of CK2 leads to the
formation of large vacuoles in pancreatic cancer cells,
related to decreased viability and autophagy induction26.
Consistent with this, we observed the formation of early
large acidic vacuoles in DLD-1 cells treated with silmita-
sertib. In fact, these vacuoles had been previously seen in
CRC cells following incubation with other less-potent
CK2 inhibitors, including apigenin and DRB, with no
explanation about their origin (Tapia J.C., personal com-
munication). These vacuoles lacked LC3 on their mem-
branes and the LC3-II and p62 levels did not correlate
with early autophagy induction53. Instead, silmitasertib
inhibited accumulation of LC3-II and p62 in presence of
bafilomycin-A1, indicative of autophagy inhibition. This
result is contradictory, considering that inhibition of CK2
with silmitasertib-promoted ULK-1 activation associated
to the inhibition of mTORC1. Although it is not possible
to rule out that the large vacuoles induced by silmitasertib
somehow mask an induction of autophagy, CK2 may have
a regulatory effect (e.g., by phosphorylation) on some key
autophagy regulators, leading finally to an attenuation of
autophagy induction after mTORC1 activation. In fact,
p62 is phosphorylated by CK2 at Ser-403, thereby favoring
autophagic clearance of ubiquitinated targets54. Likewise,
ULK-1 contains putative phosphorylation sites for CK2,
one (Thr-109) located in its kinase domain, although if the
site(s) are functionally relevant for autophagy is yet
unknown.
Silmitasertib is a well-known inducer of cell death in
different cancer cells, including CRC, although the under-
lying mechanism not only involves apoptosis but also other
non-apoptotic mechanisms. The difficulty for precisely
determine the death mechanism is probably due to the
multiple targets that CK2 phosphorylates involved in sev-
eral cancer-related processes23. Here, we determined that
the viability of CRC cells treated with this inhibitor
decreased 60–70%, of which only a 20% correspond to
apoptosis at 48 h. However, autophagy and apoptosis are
related cellular mechanisms. When autophagy is deficient
or inhibited, apoptosis is induced, and conversely autop-
hagy is induced upon deficient apoptosis15. This cross-
regulation responds to the interaction of two regulatory
proteins, Beclin-1 (autophagy inducer) and Bcl-2 (anti-
apoptotic)55, which leads to the inhibition of autophagy-
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Fig. 6 Silmitasertib-derived vacuoles are acidic but negative for LC3-II and p62. a DLD-1 cells treated with 25 μM silmitasertib for 6 h were then
labeled with 1 μM lysotracker (green) for 30 min and living cells were visualized by video-microscopy. Black arrowheads indicate the vacuoles
highlighted in white squares. Representative images are shown (n= 3), scale bars: 10 μm. b DLD-1 cells were transfected with a plasmid encoding
GFP-LC3. After a 24 h transfection, cells were treated with 25 μM silmitasertib for 6 or 12 h and visualized by confocal microscopy. White arrowheads
indicate LC3 puncta. c DLD-1 cells were treated during 6 h with 25 μM silmitasertib and/or 100 nM bafilomycin-A1 (BAF), followed by analysis of LC3-
I/II and p62 levels by western blot. d DLD-1 cells were treated with 25 μM silmitasertib and the last 3 h with 100 nM BAF, then cultured for another 3,
6, 12, and 18 h, followed by analysis of LC3-I/II levels by western blot
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associated death. Although interesting, this mechanistic
relationship was not addressed in this work and the
observed cell death remains of unknown origin.
Our findings indicate that silmitasertib induces a deep
change in the endocytic pathway of CRC cells, where large
acidic LC3-II−/LAMP1+/Rab7+ macropinosomes are
massively formed (see Fig. 8). Indeed, recent data in lit-
erature support this mechanism, since some anti-
neoplastic drugs promote massive vacuolization that
eventually leads to necrotic-like cell death, often named
methuosis42,56–58. Interestingly, the mitogen-activated
protein kinase kinase 4 (MKK4) has been indicated as a
key factor in macropinocytosis activation58 and its
downregulation is associated with liver metastasis in
CRC59. Moreover, silencing of the CK2α subunit leads to
MKK4 activation and, consequently, significant death of
PANC-1 human pancreatic cancer cells treated with
gemcitabine60, which displays methuosis-like traits.
Nevertheless, whether the putative CK2-dependent reg-
ulation of MKK4 is involved in CRC cell death as well as
decreased in vitro tumorigenesis after 21 days, is an issue
that warrants further research. Altogether, our findings
point to this selective inhibitor of CK2 as a promissory




Human normal colon cells CCD 841 (CoN) and colon
cancer cell lines (SW-480, DLD-1, HT-29 and HCT-116)
were purchased from ATCC. Cells were maintained at 37
°C and 5% CO2 in RPMI-1640 medium (Invitrogen,
Paisley, UK) supplemented with 10% Fetal Bovine Serum
(HyClone, Logan, UT), antibiotics (10000 U/ml penicillin
and 10 μg/ml streptomycin) and eventually treated with
silmitasertib (ApexBio Technology LLC, Houston, TX).
Expression vectors and transfection
The pCMV6-myr-AKT-1-CA-HA plasmid61 was pur-
chased from Addgene (Cambridge, USA) and pCMV6-
myr-AKT-1-S129A-HA was a kind gift from Dr. Maria
Ruzzene25. Expression vectors for Rab7-GFP, LAMP1-
RFP, GFP-LC3, HA-CK2α and GFP-CK2α have been
described elsewhere17,62. Small interfering RNAs (siRNA)
targeted to CK2α and control siRNA were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA).
Transfections were carried out with 2 μg each DNA by
using Lipofectamine 2000 as reagent, according to the
manufacturer’s instructions (Life Technologies, Rockford,
IL).
Western blot
Cells were lysed in RIPA buffer (Thermo Scientific,
Rockford, IL) with the cocktail of protease and phospha-
tase inhibitors PhoSTOP (Roche, Mannheim, Germany).
Proteins were separated by sodium dodecyl sulfate poly-
acrylamide gel electrophoresis, transferred to NitroPure
membranes (Macherey-Nagel, Dϋren, Germany) and
blocked with 5% BSA (Thermo Scientific, Rockford, IL) in
PBS/0.1% Tween. Blots were incubated with primary
antibodies (Cell Signaling Technology, Beverly, MA):
rabbit polyclonal anti-PARP (1:1000), rabbit polyclonal
anti-CK2α (1:1000), rabbit polyclonal anti-LC3 (1:1000),
rabbit monoclonal anti-pSer757-ULK-1 (1:1000), rabbit
monoclonal anti-ULK-1 (1:1000), rabbit monoclonal anti-
Akt (1:1000), rabbit monoclonal anti-pThr389-S6K1
(1:1000), rabbit polyclonal anti-S6K1 (1:1000), rabbit
polyclonal anti-pSer235/Ser236-S6 (1:1000) and mouse
monoclonal anti-S6 (1:1000). Mouse monoclonal anti-p62
(1:1000) was obtained from BD Biosciences and anti-actin
(1:2000) from Santa Cruz Biotechnology (Santa Cruz,
Fig. 7 Macropinocytosis-like traits of silmitasertib-derived
vacuoles in CRC cells. a DLD-1 cells were transfected with a plasmid
encoding Rab7-GFP for 24 h and then treated with 25 μM silmitasertib
for 6 h and finally visualized by confocal microscopy. b Cells were
treated with silmitasertib as in a, then incubated for 1 h with 50 μg/ml
FITC-dextran (green) and living cells were visualized by confocal
microscopy. Black arrowheads indicate the vacuoles highlighted in
white squares. Representative images are shown (n= 3); Bars: 10 μm
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CA). The secondary antibodies used were: anti-goat IgG-
HRP (1:2000), anti-rabbit IgG-HRP (1:2000) and anti-
mouse IgG-HRP (1:2000) from Santa Cruz Biotechnology.
Blots were revealed with the EZ-ECL chemiluminescent
kit (Biological Industries, Haemek, Israel).
Immunofluorescence and confocal microscopy
Cells were grown on glass coverslips for the indicated
times, washed with PBS, fixed in 3.7% p-formaldehyde for
15min, permeabilized for 10min at room temperature
(RT) in 0.2% Triton X-100/PBS (i.e., PBST), blocked with
3% BSA/PBST for 30 min at RT and incubated with pri-
mary antibody in 1% BSA/PBST (1:200 for anti-mTOR
and 1:200 for anti-HMGB1) for 1 h at RT. Incubation with
secondary antibody (1:500) was performed in 1% BSA/
PBST for 45min at RT in the dark. Lysosomes were
stained with 1 μM lysotracker for 30 min and nuclei with
DAPI for 10min (Thermo-Fisher Scientific). For dextran
uptake, cells were incubated for 1 h with 50 μg/ml FITC-
conjugated dextran (Thermo-Fisher Scientific). For some
experiments, slides were mounted in ProLong® (Life
Technologies) and images obtained with an Olympus-
IX81 DSU Spinning Disk confocal microscope. For video-
microscopy experiments, cells seeded on glass coverslips
were mounted on a microscope chamber equipped with a
heating unit (37 °C) and 5% CO2, and then analyzed by
fluorescence microscopy using an Olympus Confocal
FV1000. The program FV10-ASW 3.0 was used for all
acquisitions and settings. For determination of number
and size of vacuoles, images were taken at 20x magnifi-
cation, segmented and binarized on the ImageJ software
by homemade commands, and put all together in a macro
file. By using the /Window sincronization function on
ImageJ, circular regions corresponding to vacuoles were
tracked on binary images by contrasting them with the
original ones. Size (diameter) and number of vacuoles
identified were automatically measured by the /Multi
measure function on ImageJ.
Viability
Cells growing at 50–60% confluency on six-well plates
were transfected and/or treated with inhibitor as indicated
in the figure, left in culture during 24 h and subsequently
re-plated in 96-well plates at a density of 1 × 104 cells per
well. Viability was measured using the MTS® assay
according to the manufacturer’s instructions (Promega).
Flow cytometry
For proliferation assay, cells were detached by trypsi-
nization, washed and left in PBS to a density of 106 cells/
ml. CFSE (eBioscience) was added to a final concentration
of 5 μM, mixed for 10 s and incubated for 10min. One
volume of FBS was added, followed by complete medium
and cells were then pelleted, washed, seeded into p60 petri
dishes, and incubated with DMSO (dimethyl sulfoxide) or
silmitasertib for 48 h. For apoptosis assay, cells (2 × 105)
were washed with PBS and left in a total volume of 100 μl
binding buffer (2.5 mM CaCl2, 0.01M Hepes, 0.14M
NaCl). One microliter annexin-V-FITC (Biolegend) and
2 μl 50 μg/ml propidium iodide (PI) were added and cells
incubated for 15min at RT. Finally, 300 μl binding buffer
was added to stop the reaction. For cell cycle assay, cells
were incubated with 25 μM silmitasertib for the indicated
times and then centrifuged at 1000 x g for 5 min at RT,
washed in 1 ml cold PBS, suspended in 1ml staining
solution containing 0.1% Triton X-100, 50 μg/ml PI and
200 μg/ml RNAse, and incubated for 30 min at 37 °C in
the dark. All assays were analyzed on a Becton-Dickinson
LSR Fortessa X-20 flow cytometer and the FACSDiva
8.02 software (San Jose, CA) at the MED.UCHILE-FACS
Facility, Facultad de Medicina, Universidad de Chile.
Anchorage-independent growth
Cells (2.5 × 103) were suspended in 0.33% Bacto-agar
(BD Biosciences) in a media containing 12.5% FBS in
RPMI-1640. The cell suspension was then poured into 6-
well plates containing a layer of 2 ml 0.5% agar in the
same media. Plates were fed twice a week with 0.5 ml
RPMI-1640 supplemented with 10% FBS. After 21 days,
colonies were photographed under a Nikon Eclipse TS100
inverted microscope. Finally, cells were stained using
0.005% crystal violet dissolved in 20% methanol for 1 h at
Fig. 8 Pivotal role of CK2 in life and death of CRC cells by
regulation of methuosis. In untreated cells (left) an aberrantly
elevated expression/activity of CK2 promotes upregulation of
mTORC1 and hence downregulation of ULK-1, promoting autophagy-
independent cell viability. Here, MKK4 may also be downregulated by
CK2, thereby not affecting macropinocytosis. In silmitasertib-treated
cells (right), however, a putative MKK4-dependent macropinocytosis is
promoted, where early massive formation of acidic vacuoles (LC3-II−/
LAMP1+/Rab7+) then triggers a G2/M arrest and ultimately
methuosis-like cell death. Consequently, CRC cells are unable to form
tumors
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RT and colonies visible to the naked eye were also pho-
tographed and documented with a Nikon D5100 camera.
Migration
Migration assay was performed in Boyden Chambers of
6.5 mm diameter and 8 μm pore, according to manu-
facturer’s instructions (Transwell Costar). Briefly, the
bottom of each insert was coated with 0.5 ml 2 μg/ml
fibronectin. Cells (3.5 × 104) were suspended in serum-
free medium and seeded onto the top of each chamber
insert. Medium supplemented with 10% FBS was added to
the bottom chamber. After 8 h, inserts were removed,
washed, and cells adhered to the bottom side of the inserts
were stained with 0.1% crystal violet in 20% methanol.
The number of migrated cells was determined under a
Nikon Eclipse TS100 inverted microscope.
Reverse transcription quantitative PCR (RT-qPCR)
Total RNA from cells was extracted by using the EZNA
Total RNA Kit I (Omega bio-tek, Giorgia USA) and
treated with DNase (DNA-free Kit Ambion, Life Tech-
nologies). RNA concentration was measured with Nano-
Quant Infinite M200 pro spectrophotometer (Tecan).
Reverse transcription was performed by using the Affi-
nityScript QPCR cDNA Synthesis Kit (Agilent Technol-
ogies, TX). Quantitative real-time PCR was performed in
a StepOne real-time PCR system (Applied Biosystems)
with SYBR Green PCR master mix (Thermo-Fisher Sci-
entific, Vilnius, Lithuania). Determinations were per-
formed in triplicate (40 cycles) and the relative abundance
of each mRNA was determined by using the 2-ΔΔct
method and normalized with GAPDH. The limits of a
95% confidence interval were determined to indicate
variability of the mean ratios for each experiment. Primers
used were: Beclin-1 Fw 5´-ACCGTGTCACCATCCAGG
AA-3´ and Rv 5´-GAAGCTGTTGGCACTTTCTGT-3´.
LC3 Fw 5´-CCGTCGGAGAAGACCTTCAA-3’ and Rv
5´-GCATAGACCATGTACAGGAA-3´; GAPDH Fw 5´-
GAGTCAACGGATTTGGTCGT-3’ and Rv 5´-GACAA
GCTTCCCGTTCTCAG-3´.
Statistics
All values were expressed as mean ± SEM of three
independent experiments. Data was analyzed using two-
tailed unpaired Student’s t-test and ANOVA. p-value was
set at a nominal level of 0.05 or less.
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